ERBB2 and neoplasm: From a clinical perspective, inconsistent HER2 expression has implications on treatment efficacy, with heterogenous expression within the primary tumour being associated with shorter progression-free survival (PFS) on first-line trastuzumab-containing regimens relative to patients with homogenous expression [19,20].